Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | CASP1 | P29466 | 4/20 | 0.37 |
| ▸ | CASP7 | P55210 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | HBB | P68871 | 2/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312858 | 0.95 | CNR2 (0.38) | SYKCNR2USP2CYP1A2MEN1 | |
| SCHEMBL3451045 | 0.94 | TYRO3 (0.38) | SYKCNR2USP2CYP1A2MEN1 | |
| SCHEMBL3448967 | 0.91 | CNR2 (0.36) | SYKCNR2USP2CYP1A2MEN1 | |
| SCHEMBL3447552 | 0.91 | RAF1 (0.38) | SYKCNR2TYRO3MERTK | |
| SCHEMBL13312862 | 0.91 | CNR2 (0.35) | SYKCNR2USP2CYP1A2MEN1 | |
| SCHEMBL3373035 | 0.89 | SYK (0.43) | SYK | |
| SCHEMBL3448322 | 0.88 | SYK (0.39) | SYKCNR2USP2CYP1A2MEN1 | |
| SCHEMBL3448252 | 0.88 | CSNK2A1 (0.37) | SYKUSP2CYP1A2CASP1CASP7 | |
| SCHEMBL3451069 | 0.86 | SYK (0.38) | SYKCNR2USP2CYP1A2MEN1 | |
| SCHEMBL3450724 | 0.86 | SYK (0.44) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | SYK 804/4885CNR2 517/4885USP2 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.